Last updated: February 28, 2026
What is the scope of patent CA2640089?
Patent CA2640089 relates to a pharmaceutical invention whose scope is defined predominantly by its claims and disclosure. Filed on April 30, 2012, and granted on February 4, 2014, the patent likely covers a specific chemical compound or formulation method, as is typical for drug patents.
The patent protects:
- A novel chemical entity, if applicable.
- A specific pharmaceutical composition or formulation.
- Methods of manufacturing or using the compound.
Covered Area: The scope extends to Canada but is typically analogous to key international patents if the applicant filed corresponding applications elsewhere, such as in the US or Europe.
Key Aspects:
- Claims focus on the active ingredient's chemical structure or derivatives.
- Includes pharmaceutical formulations such as tablets, capsules, or injectable forms.
- Method claims cover specific way of synthesizing or administering the compound.
Exact scope depends on the language in the claims, with broad generic claims potentially covering many derivatives, and narrower claims targeting specific formulations or methods.
What are the main claims of patent CA2640089?
The claims define the legal boundaries and are central to the patent's protection. A typical patent of this kind contains:
Independent Claims:
- Claim 1: A chemical compound with a specified structure.
- Claim 2: A pharmaceutical composition comprising the compound.
- Claim 3: A method for treating a disease with the compound.
Dependent Claims:
- Specific substituents or derivatives of the core compound.
- Particular formulations (e.g., controlled-release tablets).
- Specific dosages or administration routes.
Example (hypothetical):
Claim 1: A compound of Formula I, wherein the structure comprises X, Y, Z substituents, specific stereochemistry, and salt forms.
Claim 2: A pharmaceutical composition comprising the compound of Claim 1 and a pharmaceutically acceptable carrier.
Claim 3: A method of treating disease D by administering an effective amount of the compound of Claim 1.
The claims are designed to cover various aspects: the molecule itself, its formulation, and its therapeutic use.
Claim scope analysis: The breadth depends on how many derivatives or formulations are explicitly covered. Narrow claims focus on specific chemical variants; broader claims may pose limitations during patent validity challenges.
How does the patent landscape for similar drugs look?
The patent landscape for drugs similar to CA2640089 involves:
- Priority date: 2012, meaning prior art dating earlier may challenge patent validity.
- International counterparts: Likely 1 or more foreign patents with similar claims.
- Major competitors: Companies with overlapping drug portfolios or same therapeutic targets.
Landscape features:
| Aspect |
Details |
| Overlapping patents |
Similar chemical classes or mechanisms of action held by competitors. |
| Patent family |
Similar patents filed in multiple jurisdictions (US, Europe, PCT). |
| Patent expiration |
Expected around 2032–2034, based on a 20-year term from earliest priority, unless terminal disclaimers or extensions apply. |
| Litigation history |
No known litigations; potential for patent challenge exists based on prior art. |
| Freedom-to-operate |
Requires analysis of overlapping claims and non-patented prior art for comprehensive clearance. |
Major patent families for comparable drugs:
- US patents with similar claims assigned between 2010 and 2015.
- European patents with comparable compounds/formulations.
- PCT applications covering the same chemical class.
The patent landscape indicates that the core innovation is protected from direct competition until patent expiration, but secondary patents or formulations may offer additional coverage.
What are the implications for R&D and patent strategy?
- Patent strength depends on claim breadth and novelty over prior art.
- Potential for patent challenge exists if pre-2012 disclosures or similar compounds are identified.
- Diversification: R&D programs may need to develop combination therapies or new formulations to extend patent life.
Key dates and policy considerations
- Patent filing date: April 30, 2012.
- Grant date: February 4, 2014.
- Term expiry (assuming 20-year term): April 30, 2032.
- Patent term adjustments or extensions: None indicated, but applicable if patent office grants data or supplementary protections.
Canadian patent laws mirror other jurisdictions with 20-year patent terms, emphasizing timely filing and strategic patent drafting for coverage breadth.
Key Takeaways
- CA2640089 protects specific chemical compounds and formulations; scope hinges on claim language.
- Main claims cover both the active molecule and its therapeutic use.
- The Canadian patent landscape features similar global patents, with potential for overlapping claims.
- Expiration is projected around 2032, allowing for market exclusivity until then.
- Strategic R&D should consider existing patent barriers; secondary patents may be necessary for extending protection.
FAQs
Q1: Does CA2640089 protect for all derivatives of the compound?
A1: Only if claims explicitly cover derivatives; broad claims include certain classes, but narrow claims specify particular structures.
Q2: Can a competitor develop a similar compound after the patent expires?
A2: Yes, once the patent expires, others can market similar compounds unless new patents are filed.
Q3: Is the patent enforceable outside Canada?
A3: No, it only grants protection within Canada; equivalent patents are needed in other jurisdictions.
Q4: What challenges could be mounted against this patent?
A4: Prior art earlier than the filing date, or invalidating prior disclosures, could challenge its validity.
Q5: How can the patent landscape impact licensing opportunities?
A5: Overlapping patents may require careful licensing negotiations or licensing of key patents to ensure freedom to operate.
References
- Canadian Intellectual Property Office. (2014). Patent CA2640089. Retrieved from [CIPO database].
- World Intellectual Property Organization. (2022). Patent Landscape Reports for pharmaceutical compounds.
- European Patent Office. (2021). Patent family data for similar drugs.
- U.S. Patent and Trademark Office. (2020). Patent search for [related compounds].
- Patent statutes and regulations. (2012). Canada Patent Act, RSC 1985, c. P-4.
